Customized Rodent Models of VEGF-Induced Retinal Leakage

Inquiry

The VEGF-induced vascular permeability model presents an opportunity for researchers to improve resistance to retinal leakage. As a CRO in ocular preclinical development, Ace Therapeutics provides our customers with validated and highly reproducible rodent models of VEGF-induced retinal leakage. This model facilitates the development and evaluation of new therapies for diabetic retinopathy and wet ADM. Here, our researchers will spare no effort to pave the way for your project to advance.

Rodent Models of VEGF-Induced Retinal Leakage

EGF and Eye Diseases

Retinal vascular damage is a hallmark of many ocular diseases, such as diabetic retinopathy (DR) and wet age-related macular degeneration (ADM). They are a significant cause of visual impairment and are increasing worldwide. Studies have shown that vascular endothelial growth factor (VEGF) plays a key role in wet ADM and DR pathogenesis. The vitreous VEGF concentration in wet ADM and DR patients is significantly increased, and anti-VEGF therapy is widely used in treatment. VEGF-induced retinal vascular injury in rodent models can well simulate human eye diseases, which can be used to evaluate the effect of anti-VEGF therapy and further improve treatment measures.

Fig. 1. VEGF-induced vascular permeability in wild-type and TSP-1-null mice. (Zhang X, et al., 2020)

Service Overview

Retinal vascular leakage is the main feature of DR and wet ADM. As a comprehensive eye disease model developer and supplier, Ace Therapeutics is committed to exploring a high-quality vascular leakage model to help our customers conduct research.

Vascular endothelial growth factor (VEGF) acts as a potent inducer of angiogenesis and vascular leakage, involved in the development, wound healing, tumor growth, macular degeneration, and ischemia. In ocular diseases, such as wet AMD and DR, VEGF is significantly upregulated. This upregulation leads to abnormal retinal blood vessel growth and leakiness, which leads to vision impairment.

In view of this, Ace Therapeutics has successfully developed a rodent model of VEGF-induced vascular permeability through continuous exploration. This model, which resembles the most devastating end-stages of wet AMD and DR, facilitates the evaluation and further development of our clients' anti-penetration strategies to ameliorate disease progression in the ocular condition. Transient retinal leaks are the main characteristics of this model.

Explore Ace Therapeutics' Rodent Models of VEGF-Induced Retinal Leakage

In Ace Therapeutics' laboratories, our researchers induce transient retinal leaks in rats by intravitreal injection of VEGF. To fully implement and validate the rodent vascular permeability model, our talented researchers have developed the following set of analytical tools, including but not limited to:

Fluorescein angiography (qualitative and quantitative analysis)
Histomorphological analysis
ELISA,
Western blotting (WB)
qPCR

Ace Therapeutics is committed to developing comprehensive and systematic ocular disease models to bring more possibilities to global customers' projects. Thanks to our in-depth understanding of retinal disease research, our expert team has successfully developed rodent models of VEGF-induced retinal leakage. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Zhang X, Kazerounian S, Duquette M, et al. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009, 23(10):3368-76.
Weis SM. Evaluation of VEGF-induced vascular permeability in mice. Methods Mol Biol. 2011, 763:403-15.
Shen WY, Lai CM, Graham CE, et al. Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model. Diabetologia. 2006, 49(7):1690-701.

For Research Use Only.

Get in Touch